^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    PTGS2 mutation

    i
    Other names: PTGS2, Prostaglandin-Endoperoxide Synthase 2, Prostaglandin G/H Synthase 2, Prostaglandin-Endoperoxide Synthase 2 (Prostaglandin G/H Synthase And Cyclooxygenase), Prostaglandin H2 Synthase 2, Cyclooxygenase 2, PGH Synthase 2, PGHS-2, PHS II, COX-2, COX2, Cyclooxygenase 2b, Cyclooxygenase-2, GRIPGHS, PGG/HS, HCox-2, PHS-2
    Entrez ID:
    5743
    Related biomarkers:
    Expression
    Others
    11ms
    Mutation of the cyclooxygenase 2 gene promoter and anastomotic leakage in colorectal cancer patients: retrospective cohort study. (PubMed, BJS Open)
    No abstract available
    Retrospective data • Journal
    |
    PTGS2 (Prostaglandin-Endoperoxide Synthase 2)
    |
    PTGS2 mutation
    1year
    Relationships of BRAF V600E Gene Mutation With Some Immunohistochemical Markers and Recurrence Rate in Patients With Thyroid Carcinoma. (PubMed, Clin Med Insights Oncol)
    The rates of positive HBME-1, COX-2, and Ki67 markers were significantly correlated to BRAF V600E gene mutation. Patients with BRAF V600E gene mutation showed a significantly higher relapse rate and earlier relapse time than those without the mutation.
    Journal
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF V600E • BRAF V600 • PTGS2 mutation
    over1year
    Triple targeting of mutant EGFR, COX-2, and 15-LOX: design and synthesis of novel quinazolinone tethered phenyl urea derivatives for anti-inflammatory and anticancer evaluation. (PubMed, J Enzyme Inhib Med Chem)
    Except for 6e and 6n, all of the tested compounds inhibited the NO production significantly more potently than celecoxib, diclofenac, and indomethacin. Docking studies confirm their favoured binding affinity. The proposed compounds could be promising multi-targeted leads.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • TNFA (Tumor Necrosis Factor-Alpha)
    |
    EGFR mutation • EGFR wild-type • PTGS2 mutation
    |
    celecoxib oral
    over2years
    Comparison of Cytotoxic and Ototoxic Effects of Lipoplatin and Cisplatin in Neuroblastoma In Vivo Tumor Model. (PubMed, J Int Adv Otol)
    For the treatment of neuroblastoma, the use of lipoplatin seems to be beneficial in reducing side effects of cisplatin. We recommend that the mechanism of these properties of lipoplatin should be evaluated in further studies.
    Preclinical • Journal
    |
    NOS2 (Nitric Oxide Synthase 2) • SOD2 (Superoxide Dismutase 2)
    |
    PTGS2 mutation
    |
    Lipoplatin (cisplatin liposomal)
    over3years
    Melatonin Modulates the Antioxidant Defenses and the Expression of Proinflammatory Mediators in Pancreatic Stellate Cells Subjected to Hypoxia. (PubMed, Antioxidants (Basel))
    Finally, melatonin diminished the phosphorylation of NF-kB and the expression of COX-2, IL-6, and TNF-α. Our results indicate that melatonin, at pharmacological concentrations, modulates the red-ox state, viability, and the expression of proinflammatory mediators in PSC subjected to hypoxia.
    Clinical • Journal
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • HMOX1 (Heme Oxygenase 1) • PTGS2 (Prostaglandin-Endoperoxide Synthase 2) • NFKBIA (NFKB Inhibitor Alpha 2) • CAT (Catalase)
    |
    HMOX1 expression • PTGS2 expression • IL6 expression • PTGS2 mutation
    over4years
    [VIRTUAL] CLINICAL PROGNOSIS OF AKT 2 AND COX2 MUTATION IN ADVANCED COLORECTAL CANCER (UEGW 2020)
    In conclusion we found that in advanced CRC the presence of AKT2 deeply on the tumor brings a worse diagnosis. In long term the correlation between the mutations is lost as well as their harmful action decreases in significance.
    Clinical
    |
    PTEN (Phosphatase and tensin homolog) • AKT2 (V-akt murine thymoma viral oncogene homolog 2)
    |
    PTEN mutation • PTGS2 mutation
    over4years
    [VIRTUAL] CLINICAL PROGNOSIS OF AKT 2 AND COX2 MUTATION IN ADVANCED COLORECTAL CANCER (UEGW 2020)
    In conclusion we found that in advanced CRC the presence of AKT2 deeply on the tumor brings a worse diagnosis. In long term the correlation between the mutations is lost as well as their harmful action decreases in significance.
    Clinical
    |
    PTEN (Phosphatase and tensin homolog) • AKT2 (V-akt murine thymoma viral oncogene homolog 2)
    |
    PTEN mutation • PTGS2 mutation
    over4years
    [VIRTUAL] CLINICAL PROGNOSIS OF AKT 2 AND COX2 MUTATION IN ADVANCED COLORECTAL CANCER (UEGW 2020)
    In conclusion we found that in advanced CRC the presence of AKT2 deeply on the tumor brings a worse diagnosis. In long term the correlation between the mutations is lost as well as their harmful action decreases in significance.
    Clinical
    |
    PTEN (Phosphatase and tensin homolog) • AKT2 (V-akt murine thymoma viral oncogene homolog 2)
    |
    PTEN mutation • PTGS2 mutation